For older children with HGG, two ongoing COG trials are evaluating novel systemic therapies together with radiotherapy depending on tumor molecular features: for patients with BRAF V600 mutant-HGG, ACNS1723 [NCT03919071] is a phase 2 trial evaluating treatment with the BRAF V600 inhibitor dabrafenib and MEK 1/2 inhibitor trametinib following radiotherapy. This evidence concerns the gene MAP2K1 and neoplasm.